DPTX3496 shows robust tumor regression and stasis in pre-clinical animal models of colorectal, breast, and lung cancer BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics Inc. – the ...
Researchers from the University of Pittsburgh have developed a new way to grow T cells in the lab that enables them to live longer and better destroy cancer cells in a mouse model of melanoma compared ...
Silexion Therapeutics shares preclinical data on SIL-204, highlighting tumor reduction in KRAS-driven cancers and sustained drug efficacy for 56+ days.